Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-491 plus chlorthalidone fixed-dose combination in uncontrolled grade 2-3 essential hypertension
NL-OMON35852Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of azilsartan medoxomil and chlorthalidone, sponsored by Takeda. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
azilsartan medoxomilchlorthalidone
Beyond the preview
Go deeper on NL-OMON35852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35852.